Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, 07745 Jena, Germany.
Clinical Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, 1090 Vienna, Austria.
J Immunol. 2018 Apr 1;200(7):2280-2290. doi: 10.4049/jimmunol.1701641. Epub 2018 Feb 26.
Factor H related-protein 5 (CFHR5) is a surface-acting complement activator and variations in the CFHR5 gene are linked to CFHR glomerulonephritis. In this study, we show that FHR5 binds to laminin-521, the major constituent of the glomerular basement membrane, and to mesangial laminin-211. Furthermore, we identify malondialdehyde-acetaldehyde (MAA) epitopes, which are exposed on the surface of human necrotic cells (), as new FHR5 ligands. Using a set of novel deletion fragments, we show that FHR5 binds to laminin-521, MAA epitopes, heparin, and human necrotic cells (HUVECs) via the middle region [short consensus repeats (SCRs) 5-7]. In contrast, surface-bound FHR5 contacts C3b via the C-terminal region (SCRs8-9). Thus, FHR5 uses separate domains for C3b binding and cell surface interaction. MAA epitopes serve as a complement-activating surface by recruiting FHR5. The complement activator FHR5 and the complement inhibitor factor H both bind to oxidation-specific MAA epitopes and FHR5 competes with factor H for binding. The C3 glomerulopathy-associated FHR2-FHR5 hybrid protein is more potent in MAA epitope binding and activation compared with wild-type FHR5. The implications of these results for pathology of CFHR glomerulonephritis are discussed. In conclusion, we identify laminins and oxidation-specific MAA epitopes as novel FHR5 ligands and show that the surface-binding site of FHR5 (SCRs5-7) is separated from the C3b binding site (SCRs8-9). Furthermore, FHR5 competes with factor H for binding to MAA epitopes and activates complement on these modified structures.
补体因子 H 相关蛋白 5(CFHR5)是一种表面作用的补体激活剂,CFHR5 基因的变异与 CFHR 肾小球肾炎有关。在这项研究中,我们表明 FHR5 结合到层粘连蛋白-521,即肾小球基底膜的主要成分,以及系膜层粘连蛋白-211。此外,我们鉴定出丙二醛-乙醛(MAA)表位,这些表位暴露在人的坏死细胞()表面,是新的 FHR5 配体。使用一组新的缺失片段,我们表明 FHR5 通过中间区域 [短共识重复(SCRs)5-7] 结合到层粘连蛋白-521、MAA 表位、肝素和人坏死细胞(HUVECs)。相比之下,表面结合的 FHR5 通过 C 末端区域(SCRs8-9)与 C3b 接触。因此,FHR5 分别使用不同的结构域进行 C3b 结合和细胞表面相互作用。MAA 表位通过募集 FHR5 充当补体激活表面。补体激活剂 FHR5 和补体抑制剂因子 H 都结合到氧化特异性 MAA 表位上,FHR5 与因子 H 竞争结合。与野生型 FHR5 相比,C3 肾小球病相关的 FHR2-FHR5 杂合蛋白在 MAA 表位结合和激活方面更为有效。这些结果对 CFHR 肾小球肾炎病理的影响进行了讨论。总之,我们确定层粘连蛋白和氧化特异性 MAA 表位为新型 FHR5 配体,并表明 FHR5 的表面结合位点(SCRs5-7)与 C3b 结合位点(SCRs8-9)分离。此外,FHR5 与因子 H 竞争结合 MAA 表位,并在这些修饰结构上激活补体。